Ocugen has announced positive 12-month topline results from its phase 2 ArMaDa clinical trial evaluating OCU410, a novel modifier gene therapy for geographic atrophy (GA) secondary to dry age-related macular degeneration (dAMD), marking a potentially significant advance in a field with limited treatment options.
The study met its primary endpoint, with the optimal (medium) dose demonstrating a statistically significant 31% reduction in GA lesion growth compared with control. This effect compares favorably with currently approved therapies, which have shown reductions of approximately 15% at 12 months and 22% at 24 months.
Additional findings point to broader structural benefits: patients treated with OCU410 showed a 27% slower rate of ellipsoid zone loss, suggesting preservation of photoreceptors, while more than half (55%) of patients achieved at least a 30% reduction in lesion size versus control. Subgroup analyses further supported efficacy, with up to a 33% reduction in lesion growth observed in selected patients.
Equally notable was the therapy’s safety profile. Investigators reported no serious adverse events or adverse events of special interest related to OCU410, and no cases of endophthalmitis, retinal detachment, vasculitis, or other major complications typically associated with retinal therapies.
Unlike existing GA treatments – which target the complement pathway and require frequent intravitreal injections – OCU410 is designed as a one-time subretinal gene therapy. It delivers the RORA (retinoid-related orphan receptor alpha) gene to modulate multiple disease pathways, including inflammation, oxidative stress, lipid metabolism, and complement activation.
Experts highlight the potential clinical impact of the treatment. “There remains a considerable unmet need in treating patients with GA,” said Lejla Vajzovic, Professor of Ophthalmology at Duke University Eye Center and Chair of the Ocugen Retina Scientific Advisory Board. “OCU410 has the potential to eliminate the chronic treatment burden associated with monthly or every-other-month intravitreal injections and to reduce treatment attrition driven by patient fatigue.”
The phase 2 trial enrolled 51 patients aged 50 years and older, with GA lesions within the non-foveval or foveal or region, randomized to receive either a single subretinal injection of OCU410 at two dose levels or no treatment. Based on these results, Ocugen plans to initiate a phase 3 registrational trial in the third quarter of 2026, with an adaptive design targeting up to 300 participants.
With GA affecting millions globally and prevalence expected to rise alongside agng populations, OCU410 may represent a promising step toward a more durable and less burdensome therapeutic strategy for patients.
Source: Ocugen.
The study met its primary endpoint, with the optimal (medium) dose demonstrating a statistically significant 31% reduction in GA lesion growth compared with control. This effect compares favorably with currently approved therapies, which have shown reductions of approximately 15% at 12 months and 22% at 24 months.
Additional findings point to broader structural benefits: patients treated with OCU410 showed a 27% slower rate of ellipsoid zone loss, suggesting preservation of photoreceptors, while more than half (55%) of patients achieved at least a 30% reduction in lesion size versus control. Subgroup analyses further supported efficacy, with up to a 33% reduction in lesion growth observed in selected patients.
Equally notable was the therapy’s safety profile. Investigators reported no serious adverse events or adverse events of special interest related to OCU410, and no cases of endophthalmitis, retinal detachment, vasculitis, or other major complications typically associated with retinal therapies.
Unlike existing GA treatments – which target the complement pathway and require frequent intravitreal injections – OCU410 is designed as a one-time subretinal gene therapy. It delivers the RORA (retinoid-related orphan receptor alpha) gene to modulate multiple disease pathways, including inflammation, oxidative stress, lipid metabolism, and complement activation.
Experts highlight the potential clinical impact of the treatment. “There remains a considerable unmet need in treating patients with GA,” said Lejla Vajzovic, Professor of Ophthalmology at Duke University Eye Center and Chair of the Ocugen Retina Scientific Advisory Board. “OCU410 has the potential to eliminate the chronic treatment burden associated with monthly or every-other-month intravitreal injections and to reduce treatment attrition driven by patient fatigue.”
The phase 2 trial enrolled 51 patients aged 50 years and older, with GA lesions within the non-foveval or foveal or region, randomized to receive either a single subretinal injection of OCU410 at two dose levels or no treatment. Based on these results, Ocugen plans to initiate a phase 3 registrational trial in the third quarter of 2026, with an adaptive design targeting up to 300 participants.
With GA affecting millions globally and prevalence expected to rise alongside agng populations, OCU410 may represent a promising step toward a more durable and less burdensome therapeutic strategy for patients.
Source: Ocugen.
